证券代码：002038 证券简称：双鹭药业 公告编号：2025-018 北京双鹭药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"或"本公司"），2024 年年度权益分 派方案已获 2025 年 5 月 22 日召开的 2024 年度股东大会审议通过，现将权益分派事宜公告 如下： 一、股东大会审议通过利润分配预案等情况 1、公司 2024 年度股东大会审议通过了《公司 2024 年度利润分配预案》：以 2024 年 12 月 31 日公司总股本 1,027,350,000 股为基数，向全体股东每 10 股派发现金红利 0.2 元 （含税），不以公积金转增股本。合计派发现金 20,547,000 元，公司剩余未分配利润 3,714,067,755.77 元结转至下一年度。 2、公司自 2024 年度权益分派方案披露至实施期间，公司股本总额未发生变化。 3、本次实施的权益分派方案与公司 2024 年度股东大会审议通过的方案一致。 4、本次实施的权益分派方案距离公司 2024 ...

Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]

Core Viewpoint - The weight loss drug concept sector has seen a significant increase, with a rise of 4.66% as of June 9, positioning it as the second-highest gaining sector in the market [1]. Group 1: Market Performance - Within the weight loss drug sector, 48 stocks experienced gains, with Changshan Pharmaceutical reaching a 20% limit up [1]. - Notable gainers include Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical, all hitting the limit up, while Xinnoway and *ST Sansheng were among the few decliners [1]. - The sector's performance is reflected in the daily gainers and losers table, highlighting the overall positive trend in the weight loss drug concept [1]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 237 million yuan from major funds, with 27 stocks receiving net inflows [1]. - Zhongsheng Pharmaceutical led the net inflow with 247 million yuan, followed by Zhifei Biological, Shuanglu Pharmaceutical, and Ganli Pharmaceutical, which also saw significant inflows [1][2]. - The net inflow ratios for leading stocks in the sector were notably high, with Zhongsheng Pharmaceutical at 55.08%, indicating strong investor interest [2][3]. Group 3: Stock Performance Metrics - Key stocks in the weight loss drug sector showed impressive daily performance metrics, with Zhongsheng Pharmaceutical and Shuanglu Pharmaceutical both achieving nearly 10% gains [2][3]. - The turnover rates for these stocks also reflect active trading, with Zhongsheng Pharmaceutical at 3.84% and Shuanglu Pharmaceutical at 7.00% [2][3]. - The data indicates a robust interest in the weight loss drug sector, as evidenced by the high net inflow ratios and significant daily price movements [2][3].

截至6月9日收盘，仿制药一致性评价概念上涨3.37%，位居概念板块涨幅第9，板块内，120股上涨，海 辰药业20%涨停，罗欣药业、昂利康、众生药业等涨停，星昊医药、一品红、万邦医药等涨幅居前，分 别上涨27.29%、9.95%、8.99%。跌幅居前的有奥赛康、海思科、复旦复华等，分别下跌1.85%、 1.16%、0.96%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.73 | 金属铅 | -0.30 | | 减肥药 | 4.66 | 供销社 | -0.05 | | 足球概念 | 4.44 | 金属铜 | 0.07 | | 创新药 | 3.91 | 金属锌 | 0.10 | | 毛发医疗 | 3.82 | 小米汽车 | 0.15 | | 阿尔茨海默概念 | 3.80 | 黄金概念 | 0.21 | | 染料 | 3.71 | 同花顺中特估100 | 0.23 | | 稀土永磁 | 3.45 | 海南自贸区 | 0.25 | | 仿制药一致性评价 | 3.37 | 低辐射玻璃(Low-E ...

星昊医药公告，持股5%以上股东北京双鹭药业（002038）股份有限公司计划减持不超过185万股，占公 司总股本的1.51%。减持方式为集中竞价或大宗交易，减持期间为公告披露之日起30个交易日后的三个 月内。减持价格将根据减持时的二级市场价格确定，减持原因为资金需求。 ...

股票代码：002038 股票简称：双鹭药业 公告编号：2025-017 北京双鹭药业股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 表决结果：同意 400,197,811 股，占出席本次股东会有效表决权股份总数的 99.2845%； 反对 1,514,775 股，占出席本次股东会有效表决权股份总数的 0.3758%；弃权 1,369,380 股（其 中，因未投票默认弃权 1,135,530 股），占出席本次股东会有效表决权股份总数的 0.3397%。 同意股数占出席会议有效表决权股份总数的 1/2 以上，该议案获得通过。 1、会议召开情况 本次股东大会由北京双鹭药业股份有限公司（以下简称"公司"）董事会召集，公司于 2025 年 4 月 22 日在《中国证券报》、巨潮资讯网（www.cninfo.com.cn）上刊登了《关于召 开 2024 年度股东大会的通知》（公告编号：2025-01 ...

lun Law Offices 北京市东城区 金宝街 89 号令宝大厦 11 层 11F Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing, Ch 电话(Tel):(86 10)6652 3388 传真(Fax):(86 10)6652 3399 网址(Website): www.junzejun.com 北京市君泽君律师事务所 关于北京双鹭药业股份有限公司 2024 年年度股东大会的法律意见 致:北京双鹭药业股份有限公司 北京双鹭药业股份有限公司（以下简称"公司"）2024年年度股东大会（以 下简称"本次股东大会")于 2025年5月22日召开,北京市君泽君律师事务所 (以下简称"本所")接受公司的委托,就公司本次股东大会的相关事宜出具法 律意见。 本所及经办律师依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则(试行)》等规定及本法律意见出具日以前已经发 生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进 行了充分的 ...

Financial Performance - The company experienced significant fluctuations in revenue and profit due to various factors, including changes in the fair value of financial assets and a high base from the previous year's demand for flu treatment drugs [2][3]. - The price reductions from centralized procurement have led to substantial decreases in the prices of key products: Temozolomide decreased by 57%, Lenalidomide by nearly 70%, and the price of Oxaliplatin injection dropped by over 80% [4]. Future Outlook - The company anticipates an improvement in performance next year, as most products involved in national procurement are newly launched and should not face significant price declines [3][4]. - The company has several new products expected to be approved, which may contribute positively to future revenue [3]. R&D and Product Development - The company is focusing on innovative drug development, with several key products in clinical trials, including DT678 and PHP1003, which are expected to address significant medical needs [7]. - The company has increased its R&D investment, with over 60% of its 400+ R&D personnel holding master's degrees or higher [14]. Market Strategy - The company is expanding its overseas market presence, particularly in developing countries, with plans to enter the European and American markets [10]. - Recent products have been included in centralized procurement, which is expected to become a new profit growth point for the company [11]. Investment and Acquisitions - Currently, the company has no plans for refinancing or mergers and acquisitions [8]. - The company holds a 55.69% stake in Beijing New Mile Health Industry Group, which is expected to yield good returns in the future [5][6]. Regulatory and Competitive Landscape - The ongoing centralized procurement policy is likely to continue, but the extent of price reductions may stabilize, leading to a more rational market environment [4]. - The company is committed to increasing R&D investment despite recent performance challenges, aiming to enhance its competitive position in the industry [4].

| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

Core Viewpoint - On its 30th anniversary, Shuanglu Pharmaceutical is facing a historic turning point, reporting a net loss of approximately 74.07 million yuan for 2024, marking its first annual loss since its listing in 2004 [1][4]. Financial Performance - In 2024, Shuanglu Pharmaceutical achieved an operating revenue of approximately 660 million yuan, a year-on-year decline of 35.15%, with a corresponding net profit of -74.07 million yuan, transitioning from profit to loss [4]. - The company had previously seen net profits exceeding 100 million yuan since 2007, peaking at 695 million yuan in 2014, and fluctuating between 200 million and 500 million yuan from 2020 to 2023 [4]. - In the first quarter of 2024, the company reported an operating revenue of approximately 169 million yuan, down 31.1%, and a net profit of approximately 45.97 million yuan, down 34.46% [4]. Product Sales Decline - Multiple key products experienced significant sales declines in 2024, with the oncology and immune regulation products generating sales of 276 million yuan, accounting for 42.69% of total sales, down 27.69% year-on-year [6]. - The sales of the previously promising product, Lenalidomide, accounted for only 4.89% of the oncology product category, with a staggering year-on-year decline of 77.22% [6][7]. - Other product categories, including anti-infection, trauma repair, and cardiovascular products, also saw sales declines of 48.42%, 30.95%, and 33.92% respectively [7]. Financial Asset Impact - The decline in financial assets, particularly the fair value changes in securities investments, significantly impacted the company's performance, with a total loss of approximately 178 million yuan from its holdings in Fosun Pharma, Shouyao Holdings, and Xinghao Pharma [9]. - The fair value changes for these stocks were -22.94 thousand yuan, -161 million yuan, and -16.14 million yuan respectively, contributing to the overall financial downturn [9]. Future Outlook - The company plans to increase R&D investment and has developed a strong product pipeline in oncology, liver disease, antiviral, metabolic regulation, and cardiovascular fields, while also exploring new areas such as diabetes and ophthalmology [5]. - The chairman expressed optimism that the company will recover its performance, viewing 2025 as a year of both challenges and opportunities [5][10].